These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 8361054

  • 1. [Effect of substrate and diluent for factor VIII activity in highly purified factor VIII concentrate and patient plasma infused factor VIII concentrate].
    Takahashi I, Furuta M, Mizuno S, Takamatsu J, Kamiya T.
    Rinsho Byori; 1993 Jul; 41(7):825-30. PubMed ID: 8361054
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The type of factor VIII deficient plasma used influences the performance of the Nijmegen modification of the Bethesda assay for factor VIII inhibitors.
    Verbruggen B, Giles A, Samis J, Verbeek K, Mensink E, Novákovà I.
    Thromb Haemost; 2001 Dec; 86(6):1435-9. PubMed ID: 11776311
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of factor VIII deficient plasmas.
    Barrowcliffe TW, Tubbs JE, Wong MY.
    Thromb Haemost; 1993 Sep 01; 70(3):433-7. PubMed ID: 8259544
    [Abstract] [Full Text] [Related]

  • 5. Bedside measurement of factor VIII:C activity in individuals with hemophilia A.
    Kessler CM, Bernstein Z, Ghesani S, Shamsipour Z, Frances C, Zucker ML, LaDuca FM.
    Am J Hematol; 1996 Mar 01; 51(3):181-5. PubMed ID: 8619397
    [Abstract] [Full Text] [Related]

  • 6. Factor VIII: C (FVIII: C) recovery and half-life after infusion of steam-treated high purity factor VIII concentrate in severe hemophilia A--comparison of one-stage assay, two-stage assay and a chromogenic substrate assay.
    Hellstern P, Kiehl R, Miyashita C, Schwerdt H, von Blohn G, Köhler M, Büttner M, Wenzel E.
    Thromb Haemost; 1986 Dec 15; 56(3):353-9. PubMed ID: 3105109
    [Abstract] [Full Text] [Related]

  • 7. Clinical application of a chromogenic substrate method for determination of factor VIII activity.
    Rosén S, Andersson M, Blombäck M, Hägglund U, Larrieu MJ, Wolf M, Boyer C, Rothschild C, Nilsson IM, Sjörin E.
    Thromb Haemost; 1985 Dec 17; 54(4):818-23. PubMed ID: 3937277
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients.
    Deitcher SR, Tuller J, Johnson JA.
    Haemophilia; 1999 Mar 17; 5(2):88-95. PubMed ID: 10215955
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Freeze-dried activated substrate for factor VIII assays.
    Margolis J.
    Dev Biol Stand; 1987 Mar 17; 67():163-7. PubMed ID: 3111909
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Development of a heat-treated factor VIII/von Willebrand factor concentrate prepared from heparinized plasma.
    Palmer DS, Ganz PR, Perkins H, Rosborough D, Rock G.
    Thromb Haemost; 1990 Jun 28; 63(3):392-402. PubMed ID: 2119525
    [Abstract] [Full Text] [Related]

  • 14. Von Willebrand factor multimers in virus-inactivated plasmas and F VIII concentrates.
    Budde U, Drewke E.
    Beitr Infusionsther Transfusionsmed; 1994 Jun 28; 32():408-14. PubMed ID: 9422121
    [Abstract] [Full Text] [Related]

  • 15. Assay discrepancies with highly purified factor VIII concentrates.
    Dawson NJ, Kemball-Cook G, Barrowcliffe TW.
    Haemostasis; 1989 Jun 28; 19(3):131-7. PubMed ID: 2501185
    [Abstract] [Full Text] [Related]

  • 16. Cold storage of citrated whole blood induces drastic time-dependent losses in factor VIII and von Willebrand factor: potential for misdiagnosis of haemophilia and von Willebrand disease.
    Böhm M, Täschner S, Kretzschmar E, Gerlach R, Favaloro EJ, Scharrer I.
    Blood Coagul Fibrinolysis; 2006 Jan 28; 17(1):39-45. PubMed ID: 16607078
    [Abstract] [Full Text] [Related]

  • 17. Preparation of factor-VIII-depleted plasma with antibodies and its use for the assay of factor VIII.
    Rothschild C, Amiral J, Adam M, Meyer D.
    Haemostasis; 1990 Jan 28; 20(6):321-8. PubMed ID: 2129163
    [Abstract] [Full Text] [Related]

  • 18. Heparin neutralization is essential for accurate measurement of factor VIII activity and inhibitor assays in blood samples drawn from implanted venous access devices.
    Manco-Johnson MJ, Nuss R, Jacobson LJ.
    J Lab Clin Med; 2000 Jul 28; 136(1):74-9. PubMed ID: 10882230
    [Abstract] [Full Text] [Related]

  • 19. Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors.
    Orsini F, Rotschild C, Beurrier P, Faradji A, Goudemand J, Polack B.
    Haematologica; 2005 Sep 28; 90(9):1288-90. PubMed ID: 16154861
    [Abstract] [Full Text] [Related]

  • 20. In vitro reactivity of factor VIII inhibitors with von Willebrand factor in different commercial factor VIII concentrates.
    Tagariello G, Zanotto D, Radossi P, Sartori R, Belvini D, Salviato R.
    Am J Hematol; 2007 Jun 28; 82(6):460-2. PubMed ID: 17211843
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.